“The present circumstance has uncovered some structural weaknesses in the EU’s medicines offer chain and also a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She suggested that offer chain difficulties be tackled within an EU pharmaceutical method predicted being released by the tip on the yr.“